Last reviewed · How we verify
Adjuvanted PBS
Adjuvanted PBS is a polyepitope peptide-based vaccine that stimulates broad immune responses against multiple influenza strains by combining conserved viral peptides with an adjuvant.
Adjuvanted PBS is a polyepitope peptide-based vaccine that stimulates broad immune responses against multiple influenza strains by combining conserved viral peptides with an adjuvant. Used for Seasonal influenza prevention.
At a glance
| Generic name | Adjuvanted PBS |
|---|---|
| Also known as | placebo |
| Sponsor | BiondVax Pharmaceuticals ltd. |
| Drug class | Peptide vaccine |
| Target | Conserved influenza viral peptide epitopes |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
PBS (Peptide-Based Seasonal) vaccine uses a multi-epitope approach targeting conserved regions of influenza proteins, combined with an adjuvant to enhance immunogenicity. The adjuvant amplifies the body's innate immune response, enabling stronger and broader T-cell and B-cell activation against multiple influenza subtypes. This approach aims to provide improved cross-strain protection compared to conventional inactivated vaccines.
Approved indications
- Seasonal influenza prevention
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Systemic reactions (fever, myalgia, fatigue)
Key clinical trials
- Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults (PHASE1, PHASE2)
- Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant (EARLY_PHASE1)
- COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 (PHASE3)
- A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) (PHASE1, PHASE2)
- A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years (PHASE1)
- Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine (PHASE1)
- Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil (PHASE1)
- Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |